

Radiation therapy for prostate cancer

Poster Session 54

Sunday, 13 March
15:45 - 17:15

Location: Room 14c (ICM, Level 1)

Chairs: D. Basic, Nis (RS)
R. Ganzer, Leipzig (DE)
R.J. Karnes, Rochester (US)

Aims and objectives of this presentation

Radiation therapy, its outcome and its morbidity for localised prostate cancer patients will be discussed in this session. An interesting prospective randomised trial comparing robotic prostatectomy and brachytherapy will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- 672 **Long term outcomes of prostate brachytherapy in Japan and recurrence predictors**
By: [Yagi Y.](#)¹, Aoki K.¹, Nakamura K.¹, Hasegawa M.¹, Ozu C.¹, Nishiyama T.¹, Shiraishi Y.², Toya K.³, Yorozu A.⁴, Saito S.¹
Institutes:¹Tokyo Medical Center, Dept. of Urology, Tokyo, Japan, ²Keio University, Dept. of Radiation Oncology, Tokyo, Japan, ³International University of Health and Welfare, Mita Hospital, Dept. of Radiation Oncology, Tokyo, Japan, ⁴Tokyo Medical Center, Dept. of Radiation Oncology, Tokyo, Japan
- 673 **Long term 15 years disease free data of LDR brachytherapy in 1700 consecutive men**
By: [Matzkin H.](#)¹, Agai R.¹, Strauss N.², Meir Y.², Mabjeesh N.¹
Institutes:¹Tel-Aviv Medical Center, Dept. of Urology, Tel Aviv, Israel, ²Tel-Aviv Medical Center, Dept. of Oncology, Tel Aviv, Israel
- 674 **Quality of Life (QoL) in patients with locally advanced prostate cancer treated with neoadjuvant endocrine, external beam radiation and adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase III trial**
By: [Yokomizo A.](#)¹, Koga H.², Ito K.³, Suzuki K.³, Yamanaka H.⁴, Naito S.²
Institutes:¹Kyushu University Graduate School of Medical Sciences, Dept. of Urology, Fukuoka, Japan, ²Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan, ³Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, ⁴Kurosawa Hospital, Dept. of Urology, Takasaki, Japan
- 675 **Urethral strictures after radiotherapy for prostate cancer - 5 year data of a certified prostate-cancer-centre**
By: [Kranz J.](#)¹, Maurer G.², Maurer U.², Deserno O.¹, Steffens J.¹
Institutes:¹St.-Antonius-Hospital, Dept. of Urology, Eschweiler, Germany, ²MVR RNR Eschweiler, Eschweiler, Germany
- 676 **Prospective evaluation of urinary function in patients with prostate cancer treated with external beam radiation therapy**
By: [Badenchini F.](#)², [Cozzarini C.](#)¹, Avuzzi B.², Fodor A.¹, Noris Chiorda B.¹, Rancati T.², Sini C.³, Valdagni R.², Di Muzio N.¹, Fiorino C.³
Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Radiotherapy, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy

- 677 **Oncological outcomes in patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase III trial**
 By: [Ito K.](#)¹, Suzuki K.¹, Yamanaka H.²
 Institutes:¹Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, ²Kurosawa Hospital, Institute for Preventive Medicine, Takasaki, Japan
- 678 **External beam radiotherapy with or without androgen deprivation therapy in very elderly patients with high metastatic risk prostate cancer**
 By: [Dell'Oglio P.](#)¹, Leyh-Bannurah S-R.², Tian Z.³, Trudeau V.¹, Larcher A.⁴, Fossati N.⁴, Moschini M.⁴, Sosa J.¹, Capitanio U.⁴, Briganti A.⁴, Graefen M.², Montorsi F.⁴, Saad F.⁵, Karakiewicz P.¹
 Institutes:¹Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ²Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, ⁴Irccs Ospedale San Raffaele, Dept. of Oncology, Unit of Urology, Uri, Milan, Italy, ⁵University of Montreal Health Center, Dept. of Urology, Montreal, Canada
- 679 **The incidence and risk of biochemical recurrence following radical radiotherapy for prostate cancer in men on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARB)**
 By: Alashkham A., Paterson C., [Nabi G.](#)
 Institutes:Ninewells Hospital, Dundee, United Kingdom
- 680 **Whole pelvis intensity-modulated arc therapy for lymph node metastasized prostate cancer: Oncologic outcomes and prognostic factors**
 By: [Poelaert F.](#)¹, Fonteyne V.², Claeys T.¹, Ost P.², Decaestecker K.¹, De Meerleer G.², D'Hondt B.¹, De Visschere P.³, Lumen N.¹
 Institutes:¹Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium, ²Universitair Ziekenhuis Gent, Dept. of Radiation Oncology, Ghent, Belgium, ³Universitair Ziekenhuis Gent, Dept. of Radiology, Ghent, Belgium
- 681 **Risk of second malignancies after iodine-125 prostate brachytherapy as monotherapy in a single institution**
 By: Fernandez A.¹, [Bucci J.](#)¹, Malouf D.², Wong K.¹, Chin Y.¹, Browne L.³
 Institutes:¹St George Hospital Cancer Care Centre, Dept. of Radiation Oncology, Kogarah, Australia, ²St George Hospital Cancer Care Centre, Dept. of Urology, Kogarah, Australia, ³St George Hospital Cancer Care Centre, Dept. of Statistics, Kogarah, Australia
- 682 **Clinico-dosimetric factors predicting long-term severe urinary incontinence after post-prostatectomy RT: Results of a longitudinal observational study**
 By: Noris Chiorda B.¹, Sini C.², Fiorino C.², Briganti A.³, Chiara A.¹, Deantoni C.¹, Fossati N.³, Gandaglia G.³, Suardi N.³, Montorsi F.³, Di Muzio N.¹, [Cozzarini C.](#)¹
 Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy
- *683 **Prospective randomized study comparing robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer**
 By: Giberti C., [Gallo F.](#), Schenone M., Cortese P., Gastaldi E., Becco D.
 Institutes:San Paolo Hospital, Dept. of Urology, Savona, Italy
- *684 **Could "radical" RT be a reasonable therapeutic option in bone oligometastatic prostate cancer patients?**
 By: Deantoni C.L.¹, [Cozzarini C.](#)¹, Fodor A.¹, Noris Chiorda B.¹, Mangili P.², Picchio M.³, Incerti E.³, Dell'Oca I.¹, Passoni P.¹, Fiorino C.², Calandrino R.², Di Muzio N.¹
 Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

*685

Evaluation of outcomes of salvage robotic prostatectomy: Single surgeon experience

By: Syed J., Christopher C., Kumar A., Samavedi S., Jenson C., Ogaya Pinies G., Ganapathi H., Bates A., Doss J., Rocco B., Coelho R., Mouraviev V., Patel V.

Institutes: Global Robotic Institute, Dept. of Urology, Celebration, United States of America